.Nature Medicine, Published online: thirteen September 2024 doi:10.1038/ s41591-024-03261-7In the non-randomized stage 3b/4 DESTINY-Breast12 research study, trastuzumab deruxtecan (T-DXd) treatment of people with HER2+ state-of-the-art breast cancer cells and also active or even dependable mind metastases presented consistent intracranial task as well as wide spread efficiency of T-DXd.